Lease Annual Net Annual Net Monthly Payment Year: Rent/RSF: Rent: Rent:Lease • March 14th, 2005 • Oragenics Inc • Pharmaceutical preparations
EXHIBIT 10.1 MEMORANDUM OF AGREEMENT Agreement, dated this 9th day of February, 2004 between iviGENE CORPORATION, of Alachua, Florida and ORAGENICS, INC., of Alachua, Florida. I. iviGene possesses certain technologies and certain target molecules...Memorandum of Agreement • August 11th, 2004 • Oragenics Inc • Pharmaceutical preparations
WHEREAS:Common Stock Purchase Agreement • May 23rd, 2005 • Oragenics Inc • Pharmaceutical preparations • Florida
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 10th, 2018 • Oragenics Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 6, 2018, between Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
DEFINITIONSSecurities Purchase Agreement • March 10th, 2006 • Oragenics Inc • Pharmaceutical preparations • Florida
BUSINESS LOAN AGREEMENTBusiness Loan Agreement • May 13th, 2005 • Oragenics Inc • Pharmaceutical preparations • Florida
Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of January 6, 2006, by and among Oragenics, Inc, a Florida corporation (the "Company"), and the persons signatory hereto (each...Registration Rights Agreement • March 10th, 2006 • Oragenics Inc • Pharmaceutical preparations • Florida
Oragenics, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of July 17, 2018Warrant Agency Agreement • July 17th, 2018 • Oragenics Inc • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of July 17, 2018 (“Agreement”), between Oragenics, Inc., a Florida corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).
Form of Representative’s Warrant Agreement WARRANT TO PURCHASE COMMON STOCK ORAGENICS, INC.Oragenics Inc • March 1st, 2024 • Pharmaceutical preparations
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ____, 2024 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (New York time) on the date that is five (5) years following the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oragenics, Inc., a Florida corporation (the “Company”), up to ______ shares of Common Stock, par value $0.001 per share, of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ORAGENICS, INC. UNDERWRITING AGREEMENT 14,189,189 Shares of Common StockUnderwriting Agreement • November 24th, 2020 • Oragenics Inc • Pharmaceutical preparations • New York
Oragenics, Inc., a company incorporated under the laws of Florida (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Oragenics, Inc., the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriter named in Schedule I hereto (the “Underwriter”), an aggregate of 14,189,189 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company also proposes to sell to the Underwriter, upon the terms and conditions set forth herein, up to an additional 2,128,378 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are collectively referred to as the “Shares.”
COMMON STOCK PURCHASE WARRANT ORAGENICS, INC.Common Stock Purchase • July 17th, 2018 • Oragenics Inc • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2018 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on , 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oragenics, Inc., a Florida corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to receive a Warrant in certifi
UNDERWRITING AGREEMENT between ORAGENICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters ORAGENICS, INC.Underwriting Agreement • March 1st, 2024 • Oragenics Inc • Pharmaceutical preparations • New York
The undersigned, Oragenics, Inc., a corporation formed under the laws of the State of Florida (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
16,666,668 SHARES OF COMMON STOCK 8,333,334 SERIES 1 WARRANTS AND 8,333,334 SERIES 2 WARRANTS OF ORAGENICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 25th, 2019 • Oragenics Inc • Pharmaceutical preparations • New York
The undersigned, Oragenics, Inc., a company incorporated under the laws of Florida (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Oragenics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which H.C. Wainwright & Co., LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK oragenics, inc.Oragenics Inc • September 5th, 2024 • Pharmaceutical preparations • New York
THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _______________, 2024 (the “Initial Exercise Date”) and until this Warrant is exercised in full, to subscribe for and purchase from Oragenics, Inc., a Florida corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to receive a Warrant in certifi
WHEREAS:Registration Rights Agreement • May 23rd, 2005 • Oragenics Inc • Pharmaceutical preparations • Florida
COMMERCIAL SECURITY AGREEMENTCommercial Security Agreement • May 13th, 2005 • Oragenics Inc • Pharmaceutical preparations • Florida
oragenics, INC. COMMON STOCK SALES AGREEMENTSales Agreement • February 1st, 2021 • Oragenics Inc • Pharmaceutical preparations • New York
Oragenics, Inc., a Florida corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 5th, 2024 • Oragenics Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September [__], 2024, between Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
AT THE MARKET OFFERING AGREEMENTThe Market Offering Agreement • February 24th, 2023 • Oragenics Inc • Pharmaceutical preparations • New York
Oragenics, Inc., a corporation organized under the laws of Florida (the “Company”), confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Manager”) as follows:
FORM OF SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 28th, 2020 • Oragenics Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 23, 2020, and is between Oragenics, Inc., a company incorporated under the laws of Florida (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT ORAGENICS, INC.Oragenics Inc • April 10th, 2018 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 6, 2018 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 10, 2023 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oragenics, Inc., a Florida corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
THIS WARRANT AND ANY SHARES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH...Common Stock Purchase Warrant • May 4th, 2020 • Oragenics Inc • Pharmaceutical preparations • Florida
This Warrant is issued pursuant to that certain Stock Purchase Agreement dated May 1, 2020 by and among the Company and the stockholder (the “Purchase Agreement”).
Oragenics, Inc.Oragenics Inc • December 28th, 2020 • Pharmaceutical preparations • New York
FORM OF REPRESENTATIVE’S COMMON STOCK PURCHASE WARRANT oragenics, inc.Oragenics Inc • June 26th, 2024 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _______________, 2024 (the “Initial Exercise Date”) and until _______________, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oragenics, Inc., a Florida corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Oragenics, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of September 4, 2024 WARRANT AGENCY AGREEMENTWarrant Agency Agreement • September 5th, 2024 • Oragenics Inc • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of September 4, 2024 (“Agreement”), between Oragenics, Inc., a Florida corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 13th, 2006 • Oragenics Inc • Pharmaceutical preparations • Florida
This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 20, 2005, by and among Oragenics, Inc, a Florida corporation (the “Company”), and the persons signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 9th, 2003 • Oragenics Inc • Pharmaceutical preparations • Florida
THIS REGISTRATION RIGHTS AGREEMENT (the "Agreement") is made and entered into as of the ____ day of April, 2002, by and among Oragenics, Inc., a Florida corporation ("Oragenics") and the purchasers listed on Schedule I hereto (each such person a "Seller" and, collectively, the "Sellers").
TRANSFER AGENT, REGISTRAR AND DIVIDEND DISBURSING AGENT AGREEMENTDisbursing Agent Agreement • December 23rd, 2002 • Oragenics Inc • Pharmaceutical preparations • British Columbia
This agreement witnesses that in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties covenant and agree as follows:
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • June 11th, 2015 • Oragenics Inc • Pharmaceutical preparations • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of June 9, 2015 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876, U.S.A. (“Intrexon”), Intrexon Actobiotics NV, a naamloze vennootschap under Belgian law with registered offices at Technologiepark 4, 9052 Zwijnaarde (CBE no. 0882.251.820 (Ghent), Belgium (“Actobiotics”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A. (“Oragenics”). Intrexon and Actobiotics together on the one hand and Oragenics on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.”
WARRANT INDENTURE _____________________________________________________________ _____________________________ THIS WARRANT INDENTURE is dated as of March 28, 2003, BETWEEN: ORAGENICS, INC., a Florida company located at 12085 Research Drive, Alachua,...Warrant Indenture • May 5th, 2003 • Oragenics Inc • Pharmaceutical preparations • British Columbia
COMPUTERSHARE TRUST COMPANY OF CANADA, a trust company incorporated under the laws of Canada and authorized to carry on trust business in the Province of British Columbia and having a branch office at 4th Floor, 510 Burrard Street, Vancouver, British Columbia, V6C 3B9
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 9th, 2017 • Oragenics Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 8th day of November, 2017 by and among Oragenics, Inc., a Florida corporation (the “Company”), and each of the several holders of Registrable Securities (as defined below) signatory hereto (each such holder, a “Holder” and, collectively, the “Holders”). Capitalized terms used herein have the respective meanings ascribed thereto in that certain Securities Purchase Agreement dated November 8, 2017 by and among the Company and the other parties signatory thereto (the “Purchase Agreement”) unless otherwise defined herein.
TRANSITION SERVICES AGREEMENTTransition Services Agreement • June 27th, 2016 • Oragenics Inc • Pharmaceutical preparations • Florida
THIS TRANSITION SERVICES AGREEMENT (this “Agreement”) is entered into as of June 24, 2016 (the “Effective Date”), by and between ProBiora Health, LLC, a Delaware limited liability company (the “Recipient”) and Oragenics, Inc., a Florida corporation (“Provider” and together with the Recipient, the “Parties”).
ESCROW AGREEMENT UNDER NATIONAL POLICY 46-201Escrow Agreement • October 16th, 2002 • Oragenics Inc • British Columbia
This Agreement is being entered into by the Parties under National Policy 46-201 Escrow for Initial Public Offerings (the Policy) in connection with the proposed distribution (the IPO), by the Issuer, an emerging issuer, of 2,000,000 Units (the "Units") consisting of one share of common stock (the "Shares"), one half of one Series A warrant (the "Series A Warrants") and one half of one Series B warrant (the "Series B Warrants") by prospectus.
ASSET PURCHASE AGREEMENT By and Among PROBIORA HEALTH, LLC, a Delaware limited liability company (“Buyer”), CHRISTINE L. KOSKI, The Sole Member and Manager of Buyer and a Personal Guarantor (“Koski”), and ORAGENICS, INC., a Florida corporation...Asset Purchase Agreement • June 23rd, 2016 • Oragenics Inc • Pharmaceutical preparations • Florida
This Asset Purchase Agreement (this “Agreement”) is entered into effective as of June 22, 2016 by and among ProBiora Health, LLC, a Delaware limited liability company (the “Buyer”), Christine L. Koski (“Koski”), the sole member and manager of Buyer and a personal guarantor (“Guarantor”) of certain of the payment obligations of Buyer, and Oragenics, Inc., a Florida corporation (the “Seller”). Buyer, Koski, and Seller are referred to collectively in this Agreement as the “Parties.”
POOLING AGREEMENTPooling Agreement • April 9th, 2003 • Oragenics Inc • Pharmaceutical preparations • British Columbia
This Agreement is being entered into by the Parties in connection with the proposed distribution (the IPO), by the Issuer, of 2,000,000 Units (the "Units") consisting of one share of common stock (the "Shares"), one half of one Series A warrant (the "Series A Warrants") and one half of one Series B warrant (the "Series B Warrants") by prospectus.
